{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:45:11Z","timestamp":1755218711984,"version":"3.43.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jns.2025.123589","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T18:54:12Z","timestamp":1750359252000},"page":"123589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Neuromyelitis Optica Spectrum disorder \u2013 Clinical profile, treatment and risk factors for relapse in three tertiary hospitals in South Africa. An observational study"],"prefix":"10.1016","volume":"475","author":[{"given":"Jerry","family":"George","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eitzaz","family":"Sadiq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Mochan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jns.2025.123589_bb0005","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jns.2025.123589_bb0010","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.jns.2025.123589_bb0015","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.jns.2025.123589_bb0020","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001089","article-title":"Neuromyelitis optica spectrum disorders in Africa: a systematic review","volume":"8","author":"Musubire","year":"2021","journal-title":"Neurol Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jns.2025.123589_bb0025","article-title":"Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis","volume":"2015","author":"Etemadifar","year":"2015","journal-title":"Mult. Scler. Int."},{"issue":"3","key":"10.1016\/j.jns.2025.123589_bb0030","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/08916934.2014.883501","article-title":"A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica","volume":"47","author":"Iyer","year":"2014","journal-title":"Autoimmunity"},{"issue":"12","key":"10.1016\/j.jns.2025.123589_bb0035","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.5588\/ijtld.10.0780","article-title":"Neuromyelitis optica and pulmonary tuberculosis: a case-control study","volume":"15","author":"Zatjirua","year":"2011","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.jns.2025.123589_bb0040","doi-asserted-by":"crossref","first-page":"1099376","DOI":"10.3389\/fneur.2023.1099376","article-title":"A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder","volume":"14","author":"Berthele","year":"2023","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2025.123589_bb0045","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic\u2019s syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jns.2025.123589_bb0050","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","article-title":"Epidemiology of neuromyelitis optica in the United States: a multicenter analysis","volume":"69","author":"Mealy","year":"2012","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2025.123589_bb0055","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40120-021-00253-4","article-title":"Neuromyelitis Optica Spectrum disorder: clinical burden and cost of relapses and disease-related care in US clinical practice","volume":"10","author":"Royston","year":"2021","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.jns.2025.123589_bb0060","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jneuroim.2016.11.010","article-title":"The clinical characteristics of AQP4 antibody positive NMO\/SD in a large cohort of Chinese Han patients","volume":"302","author":"ZhangBao","year":"2017","journal-title":"J. Neuroimmunol."},{"issue":"6","key":"10.1016\/j.jns.2025.123589_bb0065","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.jns.2025.123589_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102522","article-title":"Risk of relapse in patients with neuromyelitis optica spectrum disorder: recognition and preventive strategy","volume":"46","author":"Ma","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2025.123589_bb0075","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jns.2016.11.054","article-title":"Pregnancy in neuromyelitis optica spectrum disorder: a multicenter study from South China","volume":"372","author":"Huang","year":"2017","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.jns.2025.123589_bb0080","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/nan.12574","article-title":"Review: recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder","volume":"46","author":"Chang","year":"2020","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.jns.2025.123589_bb0085","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/ITT.S287652","article-title":"Drug treatment of neuromyelitis optica spectrum disorders: out with the old, in with the new?","volume":"10","author":"Held","year":"2021","journal-title":"Immuno.Targets Ther."},{"issue":"4","key":"10.1016\/j.jns.2025.123589_bb0090","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of neuromyelitis optica: review and recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.jns.2025.123589_bb0095","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11940-015-0387-9","article-title":"Treatment of neuromyelitis optica spectrum disorder: acute, preventive and symptomatic","volume":"18","author":"Kessler","year":"2016","journal-title":"Curr. Treat. Options Neurol."},{"issue":"3","key":"10.1016\/j.jns.2025.123589_bb0100","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1352458515587752","article-title":"Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints","volume":"22","author":"Jeong","year":"2016","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.jns.2025.123589_bb0105","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: Multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.jns.2025.123589_bb0110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) \u2013 revised recommendations of the neuromyelitis optica study group (NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel","year":"2024","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2025.123589_bb0115","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"author":"South African Government","key":"10.1016\/j.jns.2025.123589_bb0120"},{"key":"10.1016\/j.jns.2025.123589_bb0125","series-title":"Coorperative Governance anf Traditional Affairs, Editor","first-page":"13","article-title":"City of Johannesburg","author":"South African Government","year":"2020"},{"key":"10.1016\/j.jns.2025.123589_bb0130","series-title":"TB Screening Andtesting, Standard Operating Procedure","first-page":"12","author":"Department Health RoSA","year":"2023"},{"issue":"2","key":"10.1016\/j.jns.2025.123589_bb0135","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"10.1016\/j.jns.2025.123589_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J. Biomed. Inform."},{"issue":"1","key":"10.1016\/j.jns.2025.123589_bb0145","doi-asserted-by":"crossref","first-page":"684","DOI":"10.4102\/sajhivmed.v18i1.684","article-title":"The neuromyelitis optica presentation and the aquaporin-4 antibody in HIV-seropositive and seronegative patients in KwaZulu-Natal, South Africa","volume":"18","author":"Bhigjee","year":"2017","journal-title":"South Afr. J. HIV Med."},{"year":"2018","series-title":"The First National TB Prevalence Survey, South Africa","author":"Department Health RoSA","key":"10.1016\/j.jns.2025.123589_bb0150"},{"key":"10.1016\/j.jns.2025.123589_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00537","article-title":"Relapse patterns in NMOSD: evidence for earlier occurrence of optic neuritis and possible seasonal variation","volume":"11","author":"Khalilidehkordi","year":"2020","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2025.123589_bb0160","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/01.cco.0000172824.78318.b9","article-title":"Rituximab for HIV-associated lymphoma: weighing the benefits and risks","volume":"17","author":"Spina","year":"2005","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.jns.2025.123589_bb0165","series-title":"Rituximab-Related Severe Toxicity","first-page":"579","author":"Ghrenassia","year":"2018"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25002060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25002060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T09:41:24Z","timestamp":1754473284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X25002060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":33,"alternative-id":["S0022510X25002060"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2025.123589","relation":{},"ISSN":["0022-510X"],"issn-type":[{"type":"print","value":"0022-510X"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuromyelitis Optica Spectrum disorder \u2013 Clinical profile, treatment and risk factors for relapse in three tertiary hospitals in South Africa. An observational study","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2025.123589","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"123589"}}